Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.
about
Cardiac risk in the treatment of breast cancer: assessment and management.Comprehensive evaluation of microRNA expression profiling reveals the neural signaling specific cytotoxicity of superparamagnetic iron oxide nanoparticles (SPIONs) through N-methyl-D-aspartate receptorCodelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumorLiposome-Cross-Linked Hybrid Hydrogels for Glutathione-Triggered Delivery of Multiple Cargo MoleculesCo-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment.Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft modelSynergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.Polyethylene glycol modification decreases the cardiac toxicity of carbonaceous dots in mouse and zebrafish models.Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapyTumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancerMolecular-matched materials for anticancer drug delivery and imaging.A Comparative Evaluation of Hydroxycamptothecin Drug Nanorods With and Without Methotrexate Prodrug Functionalization for Drug Delivery.DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.A Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes.Glioma targeted delivery strategy of doxorubicin-loaded liposomes by dual-ligand modification.Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer.Sequential culture on biomimetic nanoclay scaffolds forms three-dimensional tumoroids.TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis.Membranes combining chitosan and natural-origin nanoliposomes for tissue engineering
P2860
Q28081385-7C6573B0-146E-4213-98F5-C551622C8EC7Q28390339-AACD9502-7529-495D-A95E-285FEE49F898Q28543911-DC652A7E-E42E-488F-ADDA-27B80C72EF90Q28829477-5F02F5E2-E135-4B75-9542-A9B96DB00177Q33742311-8DB6A27E-994A-4282-B539-2BC8306B7277Q34441761-D52E447D-6A16-482A-B264-64B1DEA68EABQ34729878-E13EAD2E-A257-479E-9EB7-4F35FFA6D576Q35751958-163427B2-AC10-4644-8AB4-F528C68736B3Q35803036-72C9BE8F-A821-4207-B6BF-429DB460B645Q35998388-DCD0A5A9-3198-446A-8E5B-2980DE002875Q36303474-EC513AF5-E77D-4C59-AF40-28C90926BC0FQ37013374-41714F87-30E9-4AC7-949E-5C14CF69D963Q37222722-CF245F7E-7A39-4A8B-8133-B1BBFD3F527DQ37621452-3D93EDFF-4C4A-4993-9ED2-F910D6E18B26Q38836010-545EC4F1-D474-46EE-9694-371AA4AD84A6Q38868191-7228E973-AD5F-46AD-8B90-E9EAA41CA8AEQ41514180-A45FD522-7562-4C0A-9C3A-8FE4D0C1B5D2Q46366459-A5943227-C4B4-4208-8615-C53A5D2D70F5Q47150459-D2602609-E3EC-49A7-9779-2C39630BB389Q47933145-99A79CEC-B58D-41C3-96DE-C1DF1E232A91Q49797582-4C162B46-690E-41E0-BB1E-8C1B3BED95C4Q51526062-93761E7B-2E09-4485-9042-A1BC6D73D94BQ54108763-02A736D4-B7E5-460F-813E-BC31486E2F4DQ57172043-C998C70E-16B9-4B0B-AFFD-71A0363112F6
P2860
Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Codelivery of doxorubicin and ...... ynergistic antitumor activity.
@ast
Codelivery of doxorubicin and ...... ynergistic antitumor activity.
@en
type
label
Codelivery of doxorubicin and ...... ynergistic antitumor activity.
@ast
Codelivery of doxorubicin and ...... ynergistic antitumor activity.
@en
prefLabel
Codelivery of doxorubicin and ...... ynergistic antitumor activity.
@ast
Codelivery of doxorubicin and ...... ynergistic antitumor activity.
@en
P2093
P2860
P356
P1476
Codelivery of doxorubicin and ...... ynergistic antitumor activity.
@en
P2093
Jinxu Fang
Michael K Wong
Yarong Liu
Yu-Jeong Kim
P2860
P304
P356
10.1021/MP5000373
P407
P577
2014-04-07T00:00:00Z